KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accumulated Expenses (2016 - 2025)

Sarepta Therapeutics has reported Accumulated Expenses over the past 15 years, most recently at $359.7 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $359.7 million for Q4 2025, up 294.71% from a year ago — trailing twelve months through Dec 2025 was $359.7 million (up 294.71% YoY), and the annual figure for FY2025 was $359.7 million, up 294.71%.
  • Accumulated Expenses for Q4 2025 was $359.7 million at Sarepta Therapeutics, up from $31.0 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for SRPT hit a ceiling of $383.7 million in Q2 2022 and a floor of $3.2 million in Q3 2021.
  • Median Accumulated Expenses over the past 5 years was $55.4 million (2022), compared with a mean of $142.9 million.
  • Biggest five-year swings in Accumulated Expenses: surged 11496.42% in 2022 and later tumbled 98.65% in 2025.
  • Sarepta Therapeutics' Accumulated Expenses stood at $271.7 million in 2021, then crashed by 75.73% to $65.9 million in 2022, then crashed by 81.7% to $12.1 million in 2023, then skyrocketed by 654.92% to $91.1 million in 2024, then soared by 294.71% to $359.7 million in 2025.
  • The last three reported values for Accumulated Expenses were $359.7 million (Q4 2025), $31.0 million (Q3 2025), and $4.7 million (Q2 2025) per Business Quant data.